ST. CLOUD HOSPITAL
- Type
- Teaching hospital
- Where
- Sartell, MN
- Medicare CCN
- 240036
- Received
- $1,193,841 in 202 records, 2023 ($18,783 general, $1,175,057 research)
- Source
- CMS Open Payments search ↗
On this site
- Business registration: St. Cloud Hospital Fuzzy (name and state)
- Business registration: St. Cloud Hospital DBA St. Benedict's Senior Community - Chateau Waters Fuzzy (name and state)
- Nonprofit contractor: St Cloud Hospital Fuzzy (name and state)
- Nonprofit: ST CLOUD HOSPITAL Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2023 | General payment | 14 | $18,783 |
| 2023 | Research payment | 188 | $1,175,057 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| Edwards Lifesciences Corporation | 22 | $542,245 | 2023 |
| Medtronic, Inc. | 19 | $232,847 | 2023 |
| Boston Scientific Corporation | 21 | $162,580 | 2023 |
| ENDOTRONIX, INC. | 1 | $75,111 | 2023 |
| Cardiovascular Systems Inc. | 6 | $23,992 | 2023 |
| Abbott Laboratories | 16 | $21,456 | 2023 |
| ABIOMED | 5 | $18,000 | 2023 |
| Esperion Therapeutics, Inc. | 76 | $15,796 | 2023 |
| PFIZER INC. | 10 | $15,450 | 2023 |
| Amgen Inc. | 2 | $14,496 | 2023 |
| Eli Lilly and Company | 2 | $13,952 | 2023 |
| AstraZeneca Pharmaceuticals LP | 2 | $11,719 | 2023 |
| AstraZeneca UK Limited | 1 | $10,792 | 2023 |
| Novartis Pharmaceuticals Corporation | 1 | $9,565 | 2023 |
| B. Braun Medical Inc. | 2 | $8,994 | 2023 |
| Stryker Corporation | 5 | $5,524 | 2023 |
| AngioDynamics, Inc. | 1 | $5,000 | 2023 |
| Linvatec Corporation | 1 | $2,409 | 2023 |
| Acerta Pharma LLC | 1 | $1,760 | 2023 |
| Olympus America Inc. | 1 | $1,052 | 2023 |
| Becton, Dickinson and Company | 1 | $353 | 2023 |
| Merck Sharp & Dohme LLC | 2 | $291 | 2023 |
| Smith+Nephew, Inc. | 2 | $222 | 2023 |
| Fisher & Paykel Healthcare Inc | 1 | $211 | 2023 |
| Organon Llc | 1 | $14 | 2023 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 188 | $1,175,057 |
| Debt forgiveness | 4 | $10,667 |
| Long term medical supply or device loan | 10 | $8,115 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2023-12-31 | Medtronic, Inc. | $6,537 | Research payment | In-kind items and services | SYMPLICITY G3 Device, Renal Denervation System | SPYRAL AFFIRM | 2023 |
| 2023-12-31 | Stryker Corporation | $3,547 | Long term medical supply or device loan | In-kind items and services | SYSTEM 7 STRYKER PRECISION Device, SURGICAL | 2023 | |
| 2023-12-31 | Linvatec Corporation | $2,409 | Long term medical supply or device loan | In-kind items and services | AIRSEAL Device, GENERAL SURGERY | 2023 | |
| 2023-12-31 | Stryker Corporation | $1,009 | Long term medical supply or device loan | In-kind items and services | PRIME SERIES Device, PATIENT HANDLING - PH | 2023 | |
| 2023-12-31 | Stryker Corporation | $620 | Debt forgiveness | Cash or cash equivalent | 2023 | ||
| 2023-12-31 | Becton, Dickinson and Company | $353 | Long term medical supply or device loan | In-kind items and services | Venclose Maven Catheter Device, Vascular/Oncology | 2023 | |
| 2023-12-31 | Merck Sharp & Dohme LLC | $287 | Research payment | In-kind items and services | JANUVIA Drug, ENDOCRINOLOGY | TECOS# A Randomized, Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes after Treatment with Sitaglip | 2023 |
| 2023-12-31 | Fisher & Paykel Healthcare Inc | $211 | Long term medical supply or device loan | In-kind items and services | FISHER & PAYKEL HEALTHCARE Device, Heated respiratory humidifier | 2023 | |
| 2023-12-31 | Stryker Corporation | $209 | Long term medical supply or device loan | In-kind items and services | COMFORTGEL Device, PATIENT HANDLING - PH | 2023 | |
| 2023-12-31 | Stryker Corporation | $137 | Long term medical supply or device loan | In-kind items and services | ISOFLEX LAL Device, PATIENT HANDLING - PH | 2023 | |
| 2023-12-31 | Merck Sharp & Dohme LLC | $3 | Research payment | Cash or cash equivalent | JANUVIA Drug, ENDOCRINOLOGY | TECOS# A Randomized, Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes after Treatment with Sitaglip | 2023 |
| 2023-12-18 | Boston Scientific Corporation | $4,584 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product IC | ACURATE IDE | 2023 |
| 2023-12-18 | Boston Scientific Corporation | $1,380 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product IC | CHAMPION AF | 2023 |
| 2023-12-15 | Medtronic, Inc. | $167,716 | Research payment | Cash or cash equivalent | SYMPLICITY G3 Device, Renal Denervation System | SPYRAL AFFIRM | 2023 |
| 2023-12-14 | Medtronic, Inc. | $3,248 | Research payment | Cash or cash equivalent | Aurora Device, Implantable Cardioverter Defibrillators (ICDs) | PSR-CVG | 2023 |
| 2023-12-14 | Medtronic, Inc. | $1,817 | Research payment | Cash or cash equivalent | Aurora Device, Implantable Cardioverter Defibrillators (ICDs) | PSR-CVG | 2023 |
| 2023-12-04 | Edwards Lifesciences Corporation | $27,228 | Research payment | Cash or cash equivalent | Early-TAVR Trial #2016-07 | 2023 | |
| 2023-12-01 | ENDOTRONIX, INC. | $75,111 | Research payment | Cash or cash equivalent | CORDELLA PULOMONARY ARTERY PRESSURE SENSOR Device, HEART FAILURE | PROACTIVE-HF | 2023 |
| 2023-11-30 | PFIZER INC. | $1,400 | Research payment | Cash or cash equivalent | XTANDI Drug, ONCOLOGY | A RANDOMIZED PHASE II TRIAL OF SALVAGE RADIOTHERAPY WITH STANDARD VS ENHANCED ANDROGEN DEPRIVATION THERAPY WITH ENZALUTA | 2023 |
| 2023-11-29 | Medtronic, Inc. | $500 | Research payment | Cash or cash equivalent | Aurora Device, Implantable Cardioverter Defibrillators (ICDs) | PSR-CVG | 2023 |
| 2023-11-20 | Edwards Lifesciences Corporation | $29,167 | Research payment | Cash or cash equivalent | THE ENCIRCLE Trial (#2018-19) | 2023 | |
| 2023-11-20 | Edwards Lifesciences Corporation | $9,066 | Research payment | Cash or cash equivalent | THE ENCIRCLE Trial (#2018-19) | 2023 | |
| 2023-11-20 | Boston Scientific Corporation | $8,243 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product IC | ACURATE IDE | 2023 |
| 2023-11-16 | Edwards Lifesciences Corporation | $27,462 | Research payment | Cash or cash equivalent | The PROGRESS Trial 2021-01 | 2023 | |
| 2023-11-14 | Abbott Laboratories | $1,750 | Research payment | Cash or cash equivalent | CARDIOMEMS Device, Heart Failure | Hemodynamic-GUIDEd Management of Heart Failure | 2023 |
| 2023-11-13 | Abbott Laboratories | $2,131 | Research payment | Cash or cash equivalent | AMPLATZER AMULET Device, Structural Heart | AMPLATZER Amulet LAA Occluder Trial (Amulet IDE) | 2023 |
| 2023-11-10 | PFIZER INC. | $500 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2023 |
| 2023-11-03 | Olympus America Inc. | $1,052 | Debt forgiveness | In-kind items and services | EVIS EXERA lll COLONOVIDEOSCOPE Device, Gastroenterology | 2023 | |
| 2023-10-26 | Edwards Lifesciences Corporation | $5,783 | Research payment | Cash or cash equivalent | ALLIANCE 2021-05 | 2023 | |
| 2023-10-23 | Boston Scientific Corporation | $610 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product IC | CHAMPION AF | 2023 |
| 2023-10-19 | Medtronic, Inc. | $1,606 | Research payment | Cash or cash equivalent | ONYX FRONTIER Device, Stents | PSR-Coronary | 2023 |
| 2023-10-16 | Boston Scientific Corporation | $19,934 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product IC | ACURATE IDE | 2023 |
| 2023-10-16 | Boston Scientific Corporation | $4,600 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product IC | ACURATE IDE | 2023 |
| 2023-10-16 | Boston Scientific Corporation | $3,000 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product IC | ACURATE IDE | 2023 |
| 2023-09-25 | Edwards Lifesciences Corporation | $21,876 | Research payment | Cash or cash equivalent | The PROGRESS Trial 2021-01 | 2023 | |
| 2023-09-25 | Edwards Lifesciences Corporation | $450 | Research payment | Cash or cash equivalent | THE ENCIRCLE Trial (#2018-19) | 2023 | |
| 2023-09-18 | Boston Scientific Corporation | $14,450 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product IC | ACURATE IDE | 2023 |
| 2023-09-18 | ABIOMED | $1,750 | Research payment | Cash or cash equivalent | Impella Device, Cardiology/Vascular Diseases | Protect IV | 2023 |
| 2023-09-18 | Boston Scientific Corporation | $357 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product IC | ACURATE IDE | 2023 |
| 2023-09-14 | Edwards Lifesciences Corporation | $17,423 | Research payment | Cash or cash equivalent | THE ENCIRCLE Trial (#2018-19) | 2023 | |
| 2023-09-08 | Medtronic, Inc. | $2,771 | Research payment | Cash or cash equivalent | Aurora Device, Implantable Cardioverter Defibrillators (ICDs) | PSR-CVG | 2023 |
| 2023-09-08 | Medtronic, Inc. | $1,272 | Research payment | Cash or cash equivalent | Aurora Device, Implantable Cardioverter Defibrillators (ICDs) | PSR-CVG | 2023 |
| 2023-09-05 | AngioDynamics, Inc. | $5,000 | Research payment | Cash or cash equivalent | ALPHAVAC Device, VIT | Evaluating the Safety and Efficacy of the AlphaVac Multipurpose Mechanical Aspiration (MMA) F1885 PE for Treatment of Ac | 2023 |
| 2023-09-05 | Edwards Lifesciences Corporation | $1,000 | Research payment | Cash or cash equivalent | The PROGRESS Trial 2021-01 | 2023 | |
| 2023-08-21 | Boston Scientific Corporation | $14,382 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product IC | ACURATE IDE | 2023 |
| 2023-08-21 | Boston Scientific Corporation | $936 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product IC | ACURATE IDE | 2023 |
| 2023-08-14 | Abbott Laboratories | $1,007 | Research payment | Cash or cash equivalent | AMPLATZER TALISMAN Device, Structural Heart | AMPLATZER PFO Occluder Post Approval Study | 2023 |
| 2023-08-10 | Edwards Lifesciences Corporation | $2,400 | Research payment | Cash or cash equivalent | Early-TAVR Trial #2016-07 | 2023 | |
| 2023-07-31 | PFIZER INC. | $4,200 | Research payment | Cash or cash equivalent | XTANDI Drug, ONCOLOGY | A RANDOMIZED PHASE II TRIAL OF SALVAGE RADIOTHERAPY WITH STANDARD VS ENHANCED ANDROGEN DEPRIVATION THERAPY WITH ENZALUTA | 2023 |
| 2023-07-31 | Abbott Laboratories | $3,068 | Research payment | Cash or cash equivalent | AMPLATZER AMULET Device, Structural Heart | AMPLATZER Amulet LAA Occluder Trial (Amulet IDE) | 2023 |
| 2023-07-21 | Esperion Therapeutics, Inc. | $750 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2023 |
| 2023-07-19 | Medtronic, Inc. | $1,258 | Research payment | Cash or cash equivalent | ONYX FRONTIER Device, Stents | PSR-Coronary | 2023 |
| 2023-07-19 | Abbott Laboratories | $921 | Research payment | Cash or cash equivalent | AMPLATZER AMULET Device, Structural Heart | Clinical Trial of Atrial Fibrillation Patients Comparing Left Atrial Appendage Occlusion Therapy to Non-vitamin K Antago | 2023 |
| 2023-07-14 | Boston Scientific Corporation | $27,000 | Research payment | Cash or cash equivalent | WATCHMAN Access System Device, WATCHMAN IC | Percutaneous Left Atrial Appendage Closure with Watchman FLX versus Standard Medical Therapy in Patients with Atrial Fi | 2023 |
| 2023-07-14 | ABIOMED | $2,000 | Research payment | Cash or cash equivalent | Impella Device, Cardiology/Vascular Diseases | Venus-HF | 2023 |
| 2023-07-14 | Abbott Laboratories | $1,562 | Research payment | Cash or cash equivalent | Diamondback Coronary Device, Vascular | Evaluation of Treatment Strategies for Severe Calcific Coronary Arteries: Orbital Atherectomy vs. Conventional Angioplas | 2023 |
| 2023-07-12 | Esperion Therapeutics, Inc. | $11,554 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2023 |
| 2023-07-06 | Edwards Lifesciences Corporation | $45,495 | Research payment | Cash or cash equivalent | Early-TAVR Trial #2016-07 | 2023 | |
| 2023-07-06 | Edwards Lifesciences Corporation | $15,068 | Research payment | Cash or cash equivalent | The PROGRESS Trial 2021-01 | 2023 | |
| 2023-06-28 | Medtronic, Inc. | $216 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | SMART Trial | 2023 |
| 2023-06-22 | Medtronic, Inc. | $1,317 | Research payment | Cash or cash equivalent | Aurora Device, Implantable Cardioverter Defibrillators (ICDs) | PSR-CVG | 2023 |
| 2023-06-22 | Medtronic, Inc. | $1,272 | Research payment | Cash or cash equivalent | Aurora Device, Implantable Cardioverter Defibrillators (ICDs) | PSR-CVG | 2023 |
| 2023-06-14 | PFIZER INC. | $500 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2023 |
| 2023-06-12 | Edwards Lifesciences Corporation | $858 | Research payment | Cash or cash equivalent | The PROGRESS Trial 2021-01 | 2023 | |
| 2023-06-09 | B. Braun Medical Inc. | $7,210 | Debt forgiveness | Cash or cash equivalent | 2023 | ||
| 2023-06-09 | B. Braun Medical Inc. | $1,783 | Debt forgiveness | Cash or cash equivalent | 2023 | ||
| 2023-06-07 | Esperion Therapeutics, Inc. | $134 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2023 |
| 2023-06-07 | Esperion Therapeutics, Inc. | $134 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2023 |
| 2023-06-07 | Esperion Therapeutics, Inc. | $134 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2023 |
| 2023-06-07 | Esperion Therapeutics, Inc. | $134 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2023 |
| 2023-06-07 | Esperion Therapeutics, Inc. | $134 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2023 |
| 2023-06-07 | Esperion Therapeutics, Inc. | $134 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2023 |
| 2023-06-07 | Esperion Therapeutics, Inc. | $131 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2023 |
| 2023-06-07 | Esperion Therapeutics, Inc. | $131 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2023 |
| 2023-06-07 | Esperion Therapeutics, Inc. | $131 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2023 |
| 2023-06-07 | Esperion Therapeutics, Inc. | $131 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2023 |
| 2023-06-07 | Esperion Therapeutics, Inc. | $131 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2023 |
| 2023-06-07 | Esperion Therapeutics, Inc. | $131 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2023 |
| 2023-06-07 | Esperion Therapeutics, Inc. | $53 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2023 |
| 2023-06-07 | Esperion Therapeutics, Inc. | $53 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2023 |
| 2023-06-07 | Esperion Therapeutics, Inc. | $53 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2023 |
| 2023-06-07 | Esperion Therapeutics, Inc. | $53 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2023 |
| 2023-06-07 | Esperion Therapeutics, Inc. | $53 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2023 |
| 2023-06-07 | Esperion Therapeutics, Inc. | $53 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2023 |
| 2023-06-07 | Esperion Therapeutics, Inc. | $35 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2023 |
| 2023-06-07 | Esperion Therapeutics, Inc. | $35 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2023 |
| 2023-06-07 | Esperion Therapeutics, Inc. | $35 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2023 |
| 2023-06-07 | Esperion Therapeutics, Inc. | $35 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2023 |
| 2023-06-07 | Esperion Therapeutics, Inc. | $35 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2023 |
| 2023-06-07 | Esperion Therapeutics, Inc. | $33 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2023 |
| 2023-06-07 | Esperion Therapeutics, Inc. | $33 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2023 |
| 2023-06-07 | Esperion Therapeutics, Inc. | $33 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2023 |
| 2023-06-07 | Esperion Therapeutics, Inc. | $33 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2023 |
| 2023-06-07 | Esperion Therapeutics, Inc. | $33 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2023 |
| 2023-06-07 | Esperion Therapeutics, Inc. | $33 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2023 |
| 2023-06-07 | Esperion Therapeutics, Inc. | $33 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2023 |
| 2023-06-07 | Esperion Therapeutics, Inc. | $33 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2023 |
| 2023-06-07 | Esperion Therapeutics, Inc. | $33 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2023 |
| 2023-06-07 | Esperion Therapeutics, Inc. | $33 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2023 |
| 2023-06-07 | Esperion Therapeutics, Inc. | $33 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2023 |
| 2023-06-07 | Esperion Therapeutics, Inc. | $33 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2023 |
| 2023-06-07 | Esperion Therapeutics, Inc. | $33 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2023 |
| 2023-06-07 | Esperion Therapeutics, Inc. | $33 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2023 |
| 2023-06-07 | Esperion Therapeutics, Inc. | $33 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2023 |
| 2023-06-07 | Esperion Therapeutics, Inc. | $33 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2023 |
| 2023-06-07 | Esperion Therapeutics, Inc. | $33 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2023 |
| 2023-06-07 | Esperion Therapeutics, Inc. | $33 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2023 |
| 2023-06-07 | Esperion Therapeutics, Inc. | $33 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2023 |
| 2023-06-07 | Esperion Therapeutics, Inc. | $33 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2023 |
| 2023-06-07 | Esperion Therapeutics, Inc. | $33 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2023 |
| 2023-06-07 | Esperion Therapeutics, Inc. | $33 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2023 |
| 2023-06-07 | Esperion Therapeutics, Inc. | $33 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2023 |
| 2023-06-07 | Esperion Therapeutics, Inc. | $33 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2023 |
| 2023-06-07 | Esperion Therapeutics, Inc. | $33 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2023 |
| 2023-06-07 | Esperion Therapeutics, Inc. | $33 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2023 |
| 2023-06-07 | Esperion Therapeutics, Inc. | $33 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2023 |
| 2023-06-07 | Esperion Therapeutics, Inc. | $33 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2023 |
| 2023-06-07 | Esperion Therapeutics, Inc. | $33 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2023 |
| 2023-06-07 | Esperion Therapeutics, Inc. | $33 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2023 |
| 2023-06-07 | Esperion Therapeutics, Inc. | $33 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2023 |
| 2023-06-07 | Esperion Therapeutics, Inc. | $25 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2023 |
| 2023-06-07 | Esperion Therapeutics, Inc. | $25 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2023 |
| 2023-06-07 | Esperion Therapeutics, Inc. | $25 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2023 |
| 2023-06-07 | Esperion Therapeutics, Inc. | $25 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2023 |
| 2023-06-07 | Esperion Therapeutics, Inc. | $25 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2023 |
| 2023-06-07 | Esperion Therapeutics, Inc. | $25 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2023 |
| 2023-06-07 | Esperion Therapeutics, Inc. | $25 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2023 |
| 2023-06-07 | Esperion Therapeutics, Inc. | $18 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2023 |
| 2023-06-07 | Esperion Therapeutics, Inc. | $16 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2023 |
| 2023-06-07 | Esperion Therapeutics, Inc. | $16 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2023 |
| 2023-06-07 | Esperion Therapeutics, Inc. | $16 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2023 |
| 2023-06-07 | Esperion Therapeutics, Inc. | $16 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2023 |
| 2023-06-07 | Esperion Therapeutics, Inc. | $16 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2023 |
| 2023-06-07 | Esperion Therapeutics, Inc. | $16 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2023 |
| 2023-06-07 | Esperion Therapeutics, Inc. | $16 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2023 |
| 2023-06-07 | Esperion Therapeutics, Inc. | $16 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2023 |
| 2023-06-07 | Esperion Therapeutics, Inc. | $16 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2023 |
| 2023-06-07 | Esperion Therapeutics, Inc. | $16 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2023 |
| 2023-06-07 | Esperion Therapeutics, Inc. | $16 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2023 |
| 2023-06-07 | Esperion Therapeutics, Inc. | $16 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2023 |
| 2023-06-01 | Organon Llc | $14 | Long term medical supply or device loan | In-kind items and services | JADA SYSTEM Device, POSTPARTUM UTERINE HEMORRHAGING | 2023 | |
| 2023-05-22 | Boston Scientific Corporation | $13,157 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product IC | ACURATE IDE | 2023 |
| 2023-05-22 | Boston Scientific Corporation | $6,446 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product IC | ACURATE IDE | 2023 |
| 2023-05-17 | Abbott Laboratories | $480 | Research payment | Cash or cash equivalent | CARDIOMEMS Device, Heart Failure | Hemodynamic-GUIDEd Management of Heart Failure | 2023 |
| 2023-05-10 | PFIZER INC. | $500 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2023 |
| 2023-05-10 | Abbott Laboratories | $303 | Research payment | Cash or cash equivalent | AMPLATZER AMULET Device, Structural Heart | Clinical Trial of Atrial Fibrillation Patients Comparing Left Atrial Appendage Occlusion Therapy to Non-vitamin K Antago | 2023 |
| 2023-05-08 | Edwards Lifesciences Corporation | $7,368 | Research payment | Cash or cash equivalent | ALLIANCE 2021-05 | 2023 | |
| 2023-05-04 | Abbott Laboratories | $1,000 | Research payment | Cash or cash equivalent | CARDIOMEMS Device, Heart Failure | Hemodynamic-GUIDEd Management of Heart Failure | 2023 |
| 2023-05-02 | Boston Scientific Corporation | $14,162 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product IC | ACURATE IDE | 2023 |
| 2023-05-01 | Medtronic, Inc. | $14,086 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | SMART Trial | 2023 |
| 2023-05-01 | Abbott Laboratories | $227 | Research payment | Cash or cash equivalent | Diamondback Coronary Device, Vascular | Evaluation of Treatment Strategies for Severe Calcific Coronary Arteries: Orbital Atherectomy vs. Conventional Angioplas | 2023 |
| 2023-04-27 | Edwards Lifesciences Corporation | $8,944 | Research payment | Cash or cash equivalent | THE ENCIRCLE Trial (#2018-19) | 2023 | |
| 2023-04-26 | Abbott Laboratories | $1,406 | Research payment | Cash or cash equivalent | AMPLATZER AMULET Device, Structural Heart | AMPLATZER Amulet LAA Occluder Trial (Amulet IDE) | 2023 |
| 2023-04-20 | Medtronic, Inc. | $5,800 | Research payment | Cash or cash equivalent | ONYX FRONTIER Device, Stents | PSR-Coronary | 2023 |
| 2023-04-20 | Medtronic, Inc. | $5,000 | Research payment | Cash or cash equivalent | ONYX FRONTIER Device, Stents | PSR-Coronary | 2023 |
| 2023-04-20 | Abbott Laboratories | $2,099 | Research payment | Cash or cash equivalent | AMPLATZER TALISMAN Device, Structural Heart | AMPLATZER PFO Occluder Post Approval Study | 2023 |
| 2023-04-17 | Boston Scientific Corporation | $6,548 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product IC | ACURATE IDE | 2023 |
| 2023-04-17 | Boston Scientific Corporation | $1,000 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product IC | CHAMPION AF | 2023 |
| 2023-04-14 | Cardiovascular Systems Inc. | $19,171 | Research payment | Cash or cash equivalent | Diamondback Coronary Device, Atherectomy Device | ECLIPSE | 2023 |
| 2023-04-13 | PFIZER INC. | $500 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2023 |
| 2023-04-06 | Edwards Lifesciences Corporation | $19,849 | Research payment | Cash or cash equivalent | THE ENCIRCLE Trial (#2018-19) | 2023 | |
| 2023-04-05 | Smith+Nephew, Inc. | $111 | Long term medical supply or device loan | In-kind items and services | LENS 4K Device, Sports Med Visualization | 2023 | |
| 2023-04-05 | Smith+Nephew, Inc. | $111 | Long term medical supply or device loan | In-kind items and services | LENS 4K Device, Sports Med Visualization | 2023 | |
| 2023-04-03 | Edwards Lifesciences Corporation | $250,717 | Research payment | Cash or cash equivalent | Early-TAVR Trial #2016-07 | 2023 | |
| 2023-04-03 | Edwards Lifesciences Corporation | $18,570 | Research payment | Cash or cash equivalent | ALLIANCE 2021-05 | 2023 | |
| 2023-04-03 | Cardiovascular Systems Inc. | $552 | Research payment | Cash or cash equivalent | Diamondback Coronary Device, Atherectomy Device | ECLIPSE | 2023 |
| 2023-03-31 | PFIZER INC. | $4,350 | Research payment | Cash or cash equivalent | XTANDI Drug, ONCOLOGY | A RANDOMIZED PHASE II TRIAL OF SALVAGE RADIOTHERAPY WITH STANDARD VS ENHANCED ANDROGEN DEPRIVATION THERAPY WITH ENZALUTA | 2023 |
| 2023-03-30 | ABIOMED | $7,500 | Research payment | Cash or cash equivalent | preCardia Device, Cardiology/Vascular Diseases | Precardia Venus-HF | 2023 |
| 2023-03-20 | Boston Scientific Corporation | $14,027 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product IC | ACURATE IDE | 2023 |
| 2023-03-16 | Medtronic, Inc. | $2,969 | Research payment | Cash or cash equivalent | Aurora Device, Implantable Cardioverter Defibrillators (ICDs) | PSR-CVG | 2023 |
| 2023-03-16 | Medtronic, Inc. | $1,272 | Research payment | Cash or cash equivalent | Aurora Device, Implantable Cardioverter Defibrillators (ICDs) | PSR-CVG | 2023 |
| 2023-03-10 | PFIZER INC. | $500 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2023 |
| 2023-03-08 | Medtronic, Inc. | $8,035 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | SMART Trial | 2023 |
| 2023-03-06 | Boston Scientific Corporation | $1,149 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product IC | CHAMPION AF | 2023 |
| 2023-03-01 | Cardiovascular Systems Inc. | $975 | Research payment | Cash or cash equivalent | Diamondback Coronary Device, Atherectomy Device | ECLIPSE | 2023 |
| 2023-02-27 | Edwards Lifesciences Corporation | $1,561 | Research payment | Cash or cash equivalent | The PROGRESS Trial 2021-01 | 2023 | |
| 2023-02-23 | Abbott Laboratories | $1,000 | Research payment | Cash or cash equivalent | AMPLATZER AMULET Device, Structural Heart | AMPLATZER Amulet LAA Occluder Trial (Amulet IDE) | 2023 |
| 2023-02-23 | Eli Lilly and Company | $384 | Research payment | In-kind items and services | THE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SU | 2023 | |
| 2023-02-15 | Abbott Laboratories | $195 | Research payment | Cash or cash equivalent | AMPLATZER TALISMAN Device, Structural Heart | AMPLATZER PFO Occluder Post Approval Study | 2023 |
| 2023-02-10 | AstraZeneca Pharmaceuticals LP | $9,370 | Research payment | Cash or cash equivalent | FARXIGA Drug, Cardiovascular and Metabolism | Dapagliflozin in Acute Decompensated Heart Failure | 2023 |
| 2023-02-09 | Edwards Lifesciences Corporation | $9,100 | Research payment | Cash or cash equivalent | The PROGRESS Trial 2021-01 | 2023 | |
| 2023-02-09 | Edwards Lifesciences Corporation | $3,250 | Research payment | Cash or cash equivalent | ALLIANCE 2021-05 | 2023 | |
| 2023-02-09 | Acerta Pharma LLC | $1,760 | Research payment | Cash or cash equivalent | CALQUENCE Drug, Oncology | A Randomized, Multicenter, Open-Label, 3 Arm Phase 3 Study of Obinutuzumab in Combination with Chlorambucil, ACP-196 in | 2023 |
| 2023-02-09 | PFIZER INC. | $500 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2023 |
| 2023-02-08 | Abbott Laboratories | $555 | Research payment | Cash or cash equivalent | AMPLATZER AMULET Device, Structural Heart | Clinical Trial of Atrial Fibrillation Patients Comparing Left Atrial Appendage Occlusion Therapy to Non-vitamin K Antago | 2023 |
| 2023-02-06 | Boston Scientific Corporation | $5,066 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product IC | ACURATE IDE | 2023 |
| 2023-02-01 | Abbott Laboratories | $3,750 | Research payment | Cash or cash equivalent | AMPLATZER AMULET Device, Structural Heart | AMPLATZER Amulet LAA Occluder Trial (Amulet IDE) | 2023 |
| 2023-02-01 | Cardiovascular Systems Inc. | $487 | Research payment | Cash or cash equivalent | Diamondback Coronary Device, Atherectomy Device | ECLIPSE | 2023 |
| 2023-01-30 | Medtronic, Inc. | $6,152 | Research payment | Cash or cash equivalent | ONYX FRONTIER Device, Stents | PSR-Coronary | 2023 |
| 2023-01-26 | Novartis Pharmaceuticals Corporation | $9,565 | Research payment | Cash or cash equivalent | LEQVIO Drug, Cardiology/Vascular Diseases | Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Car | 2023 |
| 2023-01-21 | Amgen Inc. | $2,535 | Research payment | Cash or cash equivalent | Repatha Biological, Cardiology | 20170625_VESALIUS - CV | 2023 |
| 2023-01-19 | AstraZeneca UK Limited | $10,792 | Research payment | Cash or cash equivalent | CALQUENCE Drug, Oncology | A Phase 3b, Multicenter, Open-Label, Single-Arm Study of Acalabrutinib (ACP-196) in Subjects with Chronic Lymphocytic Le | 2023 |
| 2023-01-17 | ABIOMED | $5,000 | Research payment | Cash or cash equivalent | Impella Device, Cardiology/Vascular Diseases | ECP Pivotal SUC | 2023 |
| 2023-01-17 | ABIOMED | $1,750 | Research payment | Cash or cash equivalent | Impella Device, Cardiology/Vascular Diseases | Protect IV | 2023 |
| 2023-01-13 | Cardiovascular Systems Inc. | $2,675 | Research payment | Cash or cash equivalent | Diamondback Coronary Device, Atherectomy Device | ECLIPSE | 2023 |
| 2023-01-13 | AstraZeneca Pharmaceuticals LP | $2,349 | Research payment | Cash or cash equivalent | IMFINZI Biological, Oncology | A Non-Interventional Primary Data Collection Study to Assess the Prevalence of PD-L1 High in First Line Metastatic and L | 2023 |
| 2023-01-10 | PFIZER INC. | $2,500 | Research payment | Cash or cash equivalent | XTANDI Drug, ONCOLOGY | A RANDOMIZED PHASE II TRIAL OF SALVAGE RADIOTHERAPY WITH STANDARD VS ENHANCED ANDROGEN DEPRIVATION THERAPY WITH ENZALUTA | 2023 |
| 2023-01-09 | Edwards Lifesciences Corporation | $19,604 | Research payment | Cash or cash equivalent | The PROGRESS Trial 2021-01 | 2023 | |
| 2023-01-03 | Eli Lilly and Company | $13,568 | Research payment | Cash or cash equivalent | THE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SU | 2023 | |
| 2023-01-03 | Amgen Inc. | $11,961 | Research payment | In-kind items and services | Repatha Biological, Cardiology | 20170625_VESALIUS - CV | 2023 |
The latest 200 records of 202.
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Sartell, MN, county Stearns County, MN, state Minnesota; placed by its city name.
| Measure | Place (city or town) Sartell, MN | County Stearns County, MN | State Minnesota |
|---|---|---|---|
| Population B01003 | 19,758 | 160,865 | 5,739,445 |
| Population, 2020 census P1 | 19,351 | 158,292 | 5,706,494 |
| Median age B01002 | 34.8 | 35.1 | 38.8 |
| Under 18 B01001 | 29.2% | 23.6% | 22.9% |
| 65 and over B01001 | 15.1% | 16.1% | 17.3% |
| Households B11001 | 7,630 | 61,403 | 2,307,955 |
| Foreign born B05002 | 4.2% | 7.9% | 8.7% |
| Median household income B19013 | $84,131 | $77,066 | $89,062 |
| Median family income B19113 | $117,973 | $99,842 | $113,993 |
| Per capita income B19301 | $42,415 | $38,286 | $48,237 |
| Poverty rate B17001 | 7.4% | 12.9% | 9.3% |
| Unemployment rate B23025 | 2.2% | 4.1% | 4.1% |
| Civilian labor force B23025 | 10,639 | 88,499 | 3,119,042 |
| Mean commute (minutes) B08013 | 18.8 | 21.7 | 22.7 |
| Bachelor's degree or higher B15003 | 40.9% | 28.8% | 39.4% |
| Housing units B25001 | 7,726 | 66,625 | 2,545,030 |
| Owner-occupied B25003 | 61.8% | 67.9% | 72.2% |
| Renters B25003 | 38.2% | 32.1% | 27.8% |
| Median home value B25077 | $297,300 | $273,400 | $329,300 |
| Median gross rent B25064 | $1,275 | $1,068 | $1,280 |
| White, not Hispanic B03002 | 85.1% | 80.2% | 75.9% |
| Black B03002 | 4.6% | 9.0% | 6.9% |
| Hispanic or Latino B03002 | 3.1% | 4.8% | 6.4% |
| Asian B03002 | 1.7% | 1.9% | 5.1% |
| American Indian and Alaska Native B03002 | 0.1% | 0.1% | 0.7% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Sartell, MN.
Comments